Seeking Alpha

More on Wedbush's GTx (GTXI) defense which is likely behind the stock's 9.2% premarket rally:...

More on Wedbush's GTx (GTXI) defense which is likely behind the stock's 9.2% premarket rally: "It bears repeating that … comparisons across groups of kilogram weight changes or watt power measurements" are not endpoints in the Phase III study, but "response rate for physical function" is, and the Lancet publication shows a 61% response rate vs. 39% placebo rate. Analyst David Nierengarten also says the mean/ median distinction in "the journalist's" article "ignores the design of the Phase III studies." Wedbush thinks enobosarm will meet its co-primary endpoints. (previous)
From other sites
Comments (1)
  • natera
    , contributor
    Comments (3) | Send Message
     
    Mr. Jim Creamer This is an unscrupulous speculator always recommending investment in small companies and trying to create fear in small investors regarding small company GTX, as well as one day make a purchase recommendation and the next day makes a sale therefore, I identify as a jerk speculator
    11 Jul 2013, 09:57 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector